EUVIMEDEUVIMED entdecken
EvaluationsstudieOpen Access · CC0

Caregivers of children with HIV in Botswana prefer monthly IV Broadly Neutralizing Antibodies (bNAbs) to daily oral ART

Maureen Sakoi-Mosetlhi iD, Gbolahan Ajibola iD, Roxanna Haghighat, Oganne Batlang, Kenneth Maswabi, Molly Pretorius-Holme, Kathleen M Powis, Shahin Lockman, Joseph Makhema, Mathias Litcherfeld, Daniel R Kuritzkes, Roger Shapiro

PLOS ONE · 27.03.2024 · 19 (3) · e0299942

DOI: 10.1371/journal.pone.0299942 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift PLOS ONE, online erschienen am 27.03.2024. Verfasst von Maureen Sakoi-Mosetlhi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana. Hauptthemen laut MEDLINE: HIV Infections, HIV-1. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Monthly intravenous infusion of broadly neutralizing monoclonal antibodies may be an attractive alternative to daily oral antiretroviral treatment for children living with HIV. However, acceptability among caregivers remains unknown.

Methods

We evaluated monthly infusion of dual bNAbs (VRCO1LS and 10–1074) as a treatment alternative to ART among children participating in the Tatelo Study in Botswana. Eligible children aged 2–5 years received 8–32 weeks of bNAbs overlapping with ART, and up to 24 weeks of bNAbs alone as monthly intravenous infusion. Using closed-ended questionnaires, we evaluated caregiver acceptability of each treatment strategy prior to the first bNAb administration visit (pre-intervention) and after the completion of the final bNAb administration visit (post-intervention).

Results

Twenty-five children completed the intervention phase of the study, and acceptability data were available from 24 caregivers at both time points. Responses were provided by the child’s mother at both visits (60%), an extended family member at both visits (28%), or a combination of mother and an extended family member (12%). Caregiver acceptance of monthly bNAb infusions was extremely high both pre-and post-intervention, with 21/24 (87.5%) preferring bNAbs to ART pre-intervention, and 21/25 (84%) preferring bNAbs post-intervention. While no caregiver preferred ART pre-intervention, 2/25 preferred it post-intervention. Pre-intervention, 3 (13%) caregivers had no preference between monthly bNAbs or daily ART, and 2 (8%) had no preference post-intervention. Pre-intervention, the most common reasons for preferring bNAbs over ART were the perception that bNAbs were better at suppressing the virus than ART (n = 10) and the fact that infusions were dosed once monthly compared to daily ART (n = 9). Post-intervention, no dominant reason for preferring bNAbs over ART emerged from caregivers.

Conclusions

Monthly intravenous bNAb infusions were highly acceptable to caregivers of children with HIV in Botswana and preferred over standard ART by the majority of caregivers. Clinical Trial Number NCT03707977 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHIV-1ChildFemaleHumansAntibodies, NeutralizingBotswanaBroadly Neutralizing AntibodiesCaregiversHIV AntibodiesMothers

Substanzen

Antibodies, NeutralizingBroadly Neutralizing AntibodiesHIV Antibodies

Autor:innen und Institutionen

  • Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
  • Harvard Medical School, Boston, Massachusetts, United States of America.
  • Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
  • Departments of Internal Medicine and Pediatrics, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
  • Ragon Institute of Mass General, MIT, and Harvard, Cambridge, Massachusetts, United States of America.
  • Brigham and Women's Hospital, Boston, Massachusetts, United States of America.

ORCID-Profile: Maureen Sakoi-Mosetlhi, Gbolahan Ajibola

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Sakoi-Mosetlhi, M., Ajibola, G., Haghighat, R., Batlang, O., Maswabi, K., Pretorius-Holme, M., Powis, K. M., Lockman, S., Makhema, J., Litcherfeld, M., Kuritzkes, D. R., & Shapiro, R. (2024). Caregivers of children with HIV in Botswana prefer monthly IV Broadly Neutralizing Antibodies (bNAbs) to daily oral ART. PLOS ONE, 19(3), e0299942. https://doi.org/10.1371/journal.pone.0299942

Vancouver

Sakoi-Mosetlhi M, Ajibola G, Haghighat R, Batlang O, Maswabi K, Pretorius-Holme M, et al. Caregivers of children with HIV in Botswana prefer monthly IV Broadly Neutralizing Antibodies (bNAbs) to daily oral ART. PLOS ONE. 2024;19(3):e0299942. doi:10.1371/journal.pone.0299942

BibTeX
@article{SakoiMosetlhi2024,
  author = {Sakoi-Mosetlhi, Maureen and Ajibola, Gbolahan and Haghighat, Roxanna and Batlang, Oganne and Maswabi, Kenneth and Pretorius-Holme, Molly and Powis, Kathleen M and Lockman, Shahin and Makhema, Joseph and Litcherfeld, Mathias and Kuritzkes, Daniel R and Shapiro, Roger},
  title = {Caregivers of children with HIV in Botswana prefer monthly IV Broadly Neutralizing Antibodies (bNAbs) to daily oral ART},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {3},
  pages = {e0299942},
  doi = {10.1371/journal.pone.0299942}
}
Kostenlos starten →